The novel drug-eluting contact lens is a great substitute for traditional eye drops, which are plagued by problems, such as low drug administration efficiency, discomfort,repeated dosing. Drugs can stay on the eyeball for a sufficient period of time. Patients can have access to treatment in an appropriate state at any time. With these advantages, the novel drug-eluting contact lens is expected to become a new method for the treatment of ophthalmic diseasesfor the recovery of patients after ophthalmic surgery. It has broad application prospects in the treatment of ophthalmic diseases.

The novel drug-eluting contact lens technology, in which active ingredients (medicinenutrient) are loadedslowly released, aims to improve the use of eye drops for the treatment of eye diseases. The technology is innovative, because the contact lenses carry out the loadingreleasing of active molecules through "dendritic mesoporous silica nanoparticles (DMS-NPs)," thereby forming a drug/medical material composite product. At present, no work with the same conceptfunction as our patent invention has been published in international scientific journals.

The global ophthalmology medical industry has four major fields. One of these fields is the therapeutic drug field, to which we apply our technology.  The "novel drug-eluting contact lens" can be classified as a Drug Device Combination Product. By releasing the drug actively, the drug/medical material composite product can effectively reduce the burden on the patient, thereby achieving the best therapeutic effect. Our "novel drug-eluting contact lens" technology can stablycontinuously release eye disease treatment drugsprovide solutions for the controltreatment of eye diseases.

天使投資人、策略合作夥伴